Form 4: Processa Pharmaceuticals Executive Reports Stock Transactions Following Reverse Stock Split

David Young, President of Research & Development at Processa Pharmaceuticals, reports transactions involving common stock and restricted stock units after a 20-for-1 reverse stock split.

Summary

• David Young, the President of Research & Development at Processa Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The report includes transactions from January 1, 2024, involving common stock and restricted stock units.
• A distribution of 1,675 vested restricted shares occurred.
• The filing reflects a 20-for-1 reverse stock split that Processa Pharmaceuticals implemented on January 22, 2024.
• The reported amounts of securities have been adjusted to reflect this reverse stock split.
• Following the reported transactions, Young directly owns 80,544 shares of common stock.
• Young also has indirect ownership through the Young-Plaisance Revocable Trust (30,985 shares), family entities (10,786 shares), and CorLyst, LLC (18,544 shares).
• Young directly owns 19,333 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of compliance for company insiders and provide transparency into their transactions in the company's stock. The reverse stock split is a corporate action often undertaken to increase the stock price to meet exchange listing requirements or to make the stock more attractive to investors.

Stakeholder Impact

• Shareholders are informed about insider transactions and the impact of the reverse stock split on share amounts.

Key Dates

Keywords

Form 4, beneficial ownership, Processa Pharmaceuticals, reverse stock split, David Young, stock transactions, restricted stock units, common stock